Which pathway?
Diagnosis and long-term treatment follow BTS/NICE/SIGN NG245. The adult emergency section uses the separate BTS/SIGN acute-asthma pathway; its severity thresholds and doses are for adults.
Key points
- From age 5, require a compatible history and supporting objective evidence. FeNO thresholds differ: ≥50 ppb in people over 16; ≥35 ppb at ages 5–16.
- Age 12 and over: start newly diagnosed asthma with as-needed low-dose ICS/formoterol (AIR), or low-dose MART when highly symptomatic or presenting with a severe exacerbation.
- Age 5–11: initial treatment is twice-daily paediatric low-dose ICS plus SABA as needed. Consider MART for poor control only when the child can manage the regimen.
- Do not prescribe SABA without a concomitant ICS prescription at any age. Increasing reliever use signals a need for review.
- Adult acute severe asthma: any of PEF 33–50% of best/predicted, inability to complete sentences, respiratory rate ≥25/min or pulse ≥110/min.
- Adult life-threatening features include PEF <33%, SpO₂ <92%, silent chest, poor respiratory effort, exhaustion, altered consciousness or hypotension: arrange immediate emergency care.
Overview
Asthma causes variable wheeze, cough, breathlessness and chest tightness, often worse at night or after triggers. Symptoms and examination can be normal between episodes. Record a suggestive history and objective evidence rather than diagnosing from a fixed FEV₁/FVC ratio alone. Treat an acutely unwell person immediately; perform diagnostic tests once stable if testing cannot safely be completed at presentation. Inhaled corticosteroids can make spirometry and FeNO results normal.
History and triggers
Ask about symptom variability, exercise, infections, allergic triggers, personal or family atopy, smoking and environmental exposures. In adult-onset, recurrent or poorly controlled asthma, ask whether symptoms improve away from work or on holiday; refer suspected occupational asthma to a specialist. Consider alternative causes of wheeze or breathlessness when the history or response to treatment is atypical.
Clinical Features
Symptoms
Episodic wheeze — typically worse at night and early morning
Dry cough — may be the sole presenting symptom, especially in children
Breathlessness — variable, often triggered by exercise, allergens, cold air
Chest tightness
Inability to complete sentences in one breath
Symptoms worsen with viral infections, exercise, allergens, NSAIDs, beta-blockers
Signs
Expiratory polyphonic wheeze on auscultation
Prolonged expiratory phase
Hyperinflated chest (chronic severe disease)
Silent chest — absent breath sounds indicating critical airflow limitation
Accessory muscle use, tracheal tug, inability to speak
Cyanosis, exhaustion, bradycardia, hypotension
Objective diagnosis: follow the age-specific sequence
First-line
Adults and young people over 16With a suggestive history, measure blood eosinophils OR FeNO. Diagnose if eosinophils exceed the laboratory reference range OR FeNO is ≥50 ppb.
Children aged 5–16With a suggestive history, measure FeNO first. A result ≥35 ppb supports confirmation of asthma in this pathway.
Second-line
Adult bronchodilator reversibility (BDR)If eosinophils/FeNO do not confirm asthma, diagnose with an FEV₁ increase ≥12% AND ≥200 mL from baseline, OR an increase ≥10% of predicted normal FEV₁.
BDR in children aged 5–16If FeNO is not raised or unavailable, diagnose with an FEV₁ increase ≥12% from baseline OR ≥10% of predicted normal FEV₁. The adult 200 mL requirement does not apply.
Peak-flow diary when spirometry is unavailable or delayedAt age 5 and over, record PEF twice daily for 2 weeks. Variability ≥20%, calculated as amplitude percentage mean, confirms asthma within the diagnostic pathway.
Specialist
Persistent adult diagnostic uncertaintyIf asthma remains suspected after eosinophils, FeNO, BDR or PEF testing, refer for a bronchial challenge test; bronchial hyper-responsiveness supports confirmation.
Persistent uncertainty at ages 5–16Use the NG245 allergy/eosinophil pathway: house-dust-mite skin-prick testing or total IgE plus eosinophils. Sensitisation or raised IgE with eosinophils >0.5 × 10⁹/L supports diagnosis; absent sensitisation or normal IgE argues against it. Refer persistent doubt to a paediatric specialist, including consideration of challenge testing.
Children under 5Use a monitored treatment trial and regular review; attempt objective tests from age 5. If tests cannot be performed at 5, retry every 6–12 months and refer if treatment response is inadequate.
Chronic treatment: BTS/NICE/SIGN NG245
NG245 §§1.6–1.10 and 1.141
Every age: address inflammation and check the basics
- Prescribe ICS alongside any SABA reliever. Before escalating, check adherence, inhaler technique, alternative diagnoses, comorbidities and smoking/environmental or occupational triggers.
- Give an individual written action plan. Review symptoms, reliever prescribing, steroid courses and emergency attendances; review treatment changes after 8–12 weeks.
2
Age 12 and over: initial AIR or MART
- Offer as-needed low-dose ICS/formoterol as anti-inflammatory reliever (AIR) therapy for newly diagnosed asthma.
- If highly symptomatic, for example regular nocturnal waking, or presenting with a severe exacerbation, start low-dose maintenance and reliever therapy (MART) while also treating the acute attack. MART uses the same ICS/formoterol inhaler regularly and for symptom relief.
3
Age 12 and over: uncontrolled asthma
- Uncontrolled on as-needed AIR: offer low-dose MART. Uncontrolled on low-dose MART: offer moderate-dose MART.
- If uncontrolled on moderate-dose MART despite good adherence, check FeNO if available and blood eosinophils. If either is raised, refer to an asthma specialist.
- If neither is raised, consider an 8–12 week trial of LTRA or LAMA added to moderate-dose MART. Continue if controlled; if partly improved, retain it and trial the other; if ineffective, stop it and trial the alternative. Refer if still uncontrolled after both trials, or if uncontrolled on high-dose ICS.
4
Age 12 and over: moving from older regimens
- Change confirmed asthma treated with SABA alone to as-needed low-dose ICS/formoterol.
- For uncontrolled asthma on older low-dose ICS-based regimens, consider low-dose MART; for uncontrolled moderate-dose regimens, consider moderate-dose MART. Decide whether previous add-on therapy remains useful rather than automatically continuing it.
5
Age 5–11: initial treatment and MART option
- Start twice-daily paediatric low-dose ICS with SABA as needed.
- If uncontrolled and able to manage MART, consider paediatric low-dose MART, then paediatric moderate-dose MART if needed. This is not the age-12-and-over AIR-only starting pathway.
- Symbicort Turbohaler 100/6 has a MART licence for ages 6–11. NG245 also covers age 5, for whom this use is off-label; check the exact product, age and regimen rather than treating all ICS/formoterol inhalers as interchangeable.
6
Age 5–11: when MART cannot be managed
- Consider adding an LTRA to twice-daily paediatric low-dose ICS plus SABA for 8–12 weeks; stop if ineffective.
- If still uncontrolled, offer twice-daily paediatric low-dose ICS/LABA plus SABA, then paediatric moderate-dose ICS/LABA if needed, retaining LTRA only according to previous benefit.
- Refer if uncontrolled on paediatric moderate-dose MART or paediatric moderate-dose ICS/LABA.
7
Under 5: monitored treatment trial
- Consider an 8–12 week trial of twice-daily paediatric low-dose ICS plus SABA for suspected asthma with interval symptoms suggesting maintenance treatment, or severe wheezy episodes such as hospital admission or ≥2 oral-steroid courses.
- If symptoms resolve, consider stopping ICS and SABA after the trial and review after another 3 months. Recurrence by that review, or an episode requiring systemic steroids/hospitalisation, warrants restarting regular ICS with SABA and reassessment; consider another trial off treatment within 12 months.
- If there is no response, check technique, adherence, environmental causes and alternative diagnoses before specialist referral. If uncontrolled on paediatric moderate-dose ICS, consider an 8–12 week LTRA trial; stop and refer if unsuccessful or not tolerated. Refer preschool children with a wheeze-related hospital admission or ≥2 emergency-department attendances within 12 months.
8
Inhaler and medicine safety
- Use the licensed device, strength, age range and maximum daily dose for the chosen regimen. For example, Symbicort Turbohaler 200/6 is licensed as reliever-only therapy for mild asthma from age 12; its 100/6 strength has a different licence. ICS/LABA inhalers containing a LABA other than formoterol, such as salmeterol, are not AIR/MART relievers.
- Explain montelukast neuropsychiatric risks to patients/carers. Discontinue it if new or worsening mood, behaviour or sleep-related neuropsychiatric symptoms occur and arrange review, in line with MHRA advice.
- MHRA advises treatment review when SABA is needed more than twice weekly and urgent review for increasing reliever prescriptions or failure to collect anti-inflammatory treatment.
9
Review and step down when controlled
- Discuss reducing maintenance treatment at annual review when control is good; agree monitoring and update the action plan. Allow at least 8–12 weeks between further reductions.
- For age 12 and over stepping down from low-dose maintenance ICS plus SABA or low-dose MART, use as-needed low-dose ICS/formoterol rather than SABA alone.
Adult acute severe or life-threatening asthma
Separate BTS/SIGN acute-asthma pathway (SIGN 244)1
Assess and arrange emergency care
- Any acute severe or life-threatening feature requires urgent hospital assessment; life-threatening features warrant immediate senior and intensive-care involvement. Measure PEF against personal best, or predicted if best is unknown, and oxygen saturation; obtain arterial gases when life-threatening features are present.
- These are adult severity criteria and doses. Children require the separate age-appropriate acute-asthma pathway.
2
Immediate adult hospital treatment
- Oxygen to a target SpO₂ of 94–98%; oxygen-driven nebulised salbutamol 5 mg and ipratropium bromide 0.5 mg.
- Give oral prednisolone 40–50 mg, or IV hydrocortisone 100 mg if oral treatment is unsuitable. Continue prednisolone 40–50 mg daily until recovery, for at least 5 days.
- For life-threatening disease or poor response to initial treatment, seek senior/ICU advice and consider IV magnesium sulphate 1.2–2 g over 20 minutes. Further IV bronchodilator treatment or ventilation is a senior/critical-care decision.
3
Reassess and plan follow-up
- Recheck PEF 15–30 minutes after starting treatment and escalate immediately if deteriorating or failing to improve.
- Before discharge, check inhaler technique and ongoing ICS-containing treatment, provide a written action plan and arrange GP follow-up within 2 working days and respiratory follow-up within 4 weeks.
Complications
- Acute severe/life-threatening attack: Respiratory failure requiring ventilation — the most feared complication
- Pneumothorax: Air trapping and alveolar rupture during severe exacerbation
- Fixed airflow obstruction: Airway remodelling from chronic inflammation leading to irreversible obstruction
- Growth impairment: In children on long-term systemic steroids
- Adrenal suppression: With prolonged high-dose ICS or repeated oral steroid courses
- Oral candidiasis and dysphonia: From ICS — mitigate with spacer device and mouth rinsing
UKMLA Exam Tips
- 1Separate diagnostic ages (over 16 versus 5–16) from treatment ages (12 and over, 5–11 and under 5).
- 2NICE NG245 replaces the old SABA-only starting step: age ≥12 starts with low-dose AIR, or low-dose MART if highly symptomatic; age 5–11 starts regular low-dose ICS plus SABA.
- 3Adult FeNO threshold is ≥50 ppb; at ages 5–16 it is ≥35 ppb. Adult BDR is ≥12% AND ≥200 mL, or ≥10% of predicted FEV₁; children do not need the 200 mL increment.
- 4Silent chest = life-threatening, NOT "improving" — this is the classic exam trap
- 5AIR is as-needed ICS/formoterol; MART adds regular maintenance doses of the same inhaler. Check the exact product and age licence.
- 6The adult emergency prednisolone dose is 40–50 mg daily until recovery, minimum 5 days; do not apply adult doses or severity cut-offs to children.
- 7If asked about a patient whose asthma worsened after starting an NSAID → aspirin-exacerbated respiratory disease (Samter triad: asthma + nasal polyps + NSAID sensitivity)
Put your reading into practice
Checking available topic practice…
Choose UKMLA questions from the existing bank. General exam practice covers your selected topics; it is not filtered to this article. Your usual question-bank access applies.
Choose UKMLA practiceAfter your session, return to this section to revisit the reading and choose your next review.
regional clinical guidance
Asthma: guidance by region
Recommendations, thresholds and pathways can differ. Open the page written for the jurisdiction you need.
Verified Sources & References
BTS/NICE/SIGN NG245 — diagnosis, monitoring and chronic asthma management (including November 2025 licensing notes)
BTS/NICE/SIGN asthma pathway — adult acute hospital management (SIGN 244)
MHRA — SABA overuse and ICS prescribing (24 April 2025)
MHRA — montelukast neuropsychiatric reactions (29 April 2024)
Symbicort Turbohaler 100/6 — current SmPC, including MART at ages 6–11
Symbicort Turbohaler 200/6 — current SmPC, including reliever therapy from age 12
related resources
Save your place and choose what comes next
Respiratory · Article 1 of 20